ArticleClinical rheumatology2026
Targeting the FoxO-ferroptosis axis: mechanistic insights into Saikosaponin A-mediated protection against cartilage degeneration in osteoarthritis.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundOsteoarthritis (OA) is a common chronic inflammatory orthopedic disease, and ferroptosis (a novel OA-associated cell death mechanism) remains insufficiently understood. Saikosaponin A (a traditional Chinese medicine monomer) shows OA therapeutic effects, but its role in OA-related ferroptosis is unclear. This study aimed to elucidate its mechanism via bioinformatics, single-cell analysis, and in vitro/in vivo experiments.
methodsOA expression profiles (GEO: GSE1919, GSE55235, GSE55475) and ferroptosis genes (FerrDb) were collected. Machine learning identified OA ferroptosis hub genes and pathways; scRNA-seq (GSE169454, Seurat/SCENIC) defined chondrocyte subsets. Network pharmacology and experiments (human primary chondrocytes, MIA-KOA rats) validated targets.
resultsBioinformatics and network pharmacology analysis revealed that Saikosaponin A mediates chondrocyte ferroptosis via the TNF signaling pathway and FoxO signaling pathway through the regulation of MAPK14, MAPK8, SOX2, IL1B, NR4A1, and PTGS2. Subsequent in vitro and in vivo experiments confirmed that Saikosaponin A can alleviate the progression of KOA by regulating chondrocyte ferroptosis through the FoxO signaling pathway. Finally, single-cell combined bioinformatics analysis further expanded the relationship between core genes and chondrocyte subtypes.
conclusionThis study systematically elucidated that Saikosaponin A can regulate FoxO signaling pathway to modulate chondrocyte ferroptosis and alleviate the progression of KOA, and that MAPK14, MAPK8, SOX2, IL1B, NR4A1, and PTGS2 are involved in the regulation of chondrocyte phenotype. Key Points • Integrated multi-omics approach identifies the FoxO-ferroptosis axis in OA. Combining bioinformatics, network pharmacology, and single-cell sequencing revealed the crucial role of the FoxO signaling pathway in regulating chondrocyte ferroptosis during osteoarthritis (OA) progression. • Saikosaponin A alleviates chondrocyte ferroptosis via the FoxO pathway. Both in vitro and in vivo experiments demonstrate that the natural compound Saikosaponin A inhibits erastin-induced ferroptosis in chondrocytes by targeting key components of the FoxO signaling pathway (FoxO1 and PI3K). • MAPK14, MAPK8, SOX2, IL1B, NR4A1, and PTGS2 are key regulatory genes. Multi-dataset analysis pinpointed six hub genes linking ferroptosis to OA, which are involved in Saikosaponin A's therapeutic mechanism. • Single-cell analysis maps ferroptosis hub genes to specific chondrocyte subtypes. The study unveils the distinct distribution of ferroptosis-related regulators (e.g., high PTGS2 in ProCs and RegCs) across chondrocyte subpopulations, providing cellular-level insights for targeted therapy.
Indexed as
Identifiers
42474670What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.